Keytruda

(Pembrolizumab)

Phase 3Monoclonal antibody

Pembrolizumab is used to treat certain types of cancer, including melanoma and lung cancer, by helping the immune system recognize and attack cancer cells.[1] Keytruda is currently being investigated across 314 indications[3], with its most advanced program in Phase 3.[1]

Keytruda is one of 2404 monoclonal antibody programs targeting Glioma. It is currently in Phase 3.

314

Indications

2,178

Total Trials

Active Trials

2,403

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

GliomaActive, not recruiting

Head and Neck CarcinomaActive, not recruiting

Small Cell CarcinomaActive, not recruiting

Collecting Duct CarcinomaActive, not recruiting

Pancreatic NeoplasmActive, not recruiting

Gestational Trophoblastic NeoplasmActive, not recruiting

HIV InfectionActive, not recruiting

Gastroesophageal Junction AdenocarcinomaActive, not recruiting

ChordomaActive, not recruiting

AscitesActive, not recruiting

GliomaPhase 1

Active, not recruiting

Head and Neck CarcinomaPhase 1

Active, not recruiting

Small Cell CarcinomaPreclinical

Active, not recruiting

Collecting Duct CarcinomaPhase 2

Active, not recruiting

Pancreatic NeoplasmPhase 2

Active, not recruiting

Gestational Trophoblastic NeoplasmPhase 2

Active, not recruiting

HIV InfectionPhase 1

Active, not recruiting

Gastroesophageal Junction AdenocarcinomaPhase 3

Active, not recruiting

ChordomaPhase 2

Active, not recruiting

AscitesPreclinical

Active, not recruiting

Showing 10 of 313 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

98 2

Halaven

Eisai

Preclinical

38 3

Avastin

Megace

4 5

Voltaren

Novartis

Preclinical

1 6

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 7

Recentin

NNational Cancer Institute (NCI)

Preclinical

2 8

Spravato

WWim Janssens

Preclinical

2 9

Tricor

JJagotec

Preclinical

1 10

Avastin

Roche

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Recruiting

Non-Small Cell Lung Cancer

NCT04253964

Q4 2026

Phase 3Active, not recruiting

Non-Small Cell Lung Cancer

NCT04956692

Phase 3Active, not recruiting

Renal Cell Carcinoma

NCT04736706

Phase 2Active, not recruiting

Patients With Advanced Solid Tumors

NCT02644369

Phase 2Recruiting

Esophageal Adenocarcinoma

NCT04069273

Phase 2Recruiting

Lymphoma

NCT05355051

Clinical

Trials by Indication[1]

Pembrolizumab18 trials

Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL

Active, not recruiting·UUniversity of Virginia·Phase 1·NCT03240211·37 enrolled

64Cu-DOTA-pembrolizumab PET for the Study of PD1 Expression

Withdrawn·—·Phase 1·NCT04605614

Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT02721732·157 enrolled

Show 15 more trials

A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors

Completed·HHalozyme Therapeutics·Phase 1·NCT02563548·56 enrolled

Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults

Completed·—·Phase 1·NCT03445858·22 enrolled

Study Evaluating Pembrolizumab +/- Olaparib in TLS Positive Selected Resectable STS Followed by Adjuvant Pembrolizumab

Withdrawn·GGustave Roussy, Cancer Campus, Grand Paris·Phase 2·NCT06116578

OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC

Active, not recruiting·AARCAGY/ GINECO GROUP·Phase 2·NCT04713514·180 enrolled

Pembrolizumab and Chemotherapy Neoadjuvant/Adjuvant of NSCLC

Active, not recruiting·PPeking University·Phase 2·NCT05894889·70 enrolled

Chemotherapy With Pembrolizumab Continuation After Progression to PD-1/L1 Inhibitors

Unknown status·SSamsung Medical Center·Phase 2·NCT03656094·98 enrolled

Pembrolizumab Activity in Patients With Homologous Recombination Competent and Deficient Tumors

Completed·BBaptist Health South Florida·Phase 2·NCT03274661·52 enrolled

Pembrolizumab + MRGOO3 as Neoadjuvant in NPC

Not yet recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 2·NCT07267338·35 enrolled

Addition of Pembrolizumab to the Standard of Care Chemotherapy in Patient With SCCOHT

Recruiting·AARCAGY/ GINECO GROUP·Phase 2·NCT04602377·27 enrolled

Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC

Recruiting·UUNICANCER·Phase 2·NCT06078384·354 enrolled

First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLC

Recruiting·XXiaorong Dong·Phase 2·NCT05745350·45 enrolled

Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b

Completed·YYana Najjar·Phase 1·NCT02339324·31 enrolled

Case Review of Patients With Betel Nut-induced Oral Cancer Treated With Pembrolizumab and Cetuximab

Completed·CCommonwealth Healthcare Corporation··NCT07015333·31 enrolled

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

Recruiting·—·Phase 2·NCT04468061·110 enrolled

A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab

Completed·LLeap Therapeutics, Inc.·Phase 1·NCT02013154·151 enrolled

Breast Cancer16 trials

Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer

Recruiting·NNorthwestern University·Phase 2·NCT03213041·100 enrolled

Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer

Recruiting·JJiangsu Alphamab Biopharmaceuticals Co., Ltd·Phase 1/2·NCT06942234·180 enrolled

Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer

Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT05177796

Show 13 more trials

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

Recruiting·SSWOG Cancer Research Network·Phase 3·NCT05929768·2,400 enrolled

Converting HR+ Breast Cancer Into an Individualized Vaccine

Recruiting·WWeill Medical College of Cornell University·Phase 2·NCT03804944·100 enrolled

Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer

Completed·—·Phase 2·NCT02971761·18 enrolled

Phase 2 Study of Pembrolizumab+Carboplatin in Breast Related Cancer Antigens-related Metastatic Breast Cancer (PEMBRACA)

Completed·CCORTESI LAURA·Phase 2·NCT03732391·22 enrolled

Pembrolizumab and Paclitaxel in Hormone Receptor-positive, hyperMUTATted Metastatic Breast Cancer Identified by Whole exOme sequeNcing ('MUTATION2')

Unknown status·YYonsei University·Phase 2·NCT04946227·52 enrolled

Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer

Recruiting·NNational University Hospital, Singapore·Phase 1/2·NCT05491083·51 enrolled

Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT04191135·462 enrolled

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Recruiting·QQuantumLeap Healthcare Collaborative·Phase 2·NCT01042379·5,000 enrolled

Pembrolizumab and Exemestane/ Leuprolide in Premenopausal HR+/ HER2- Locally Advanced or Metastatic Breast Cancer

Terminated·NNational Taiwan University Hospital·Phase 1/2·NCT02990845·16 enrolled

Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 Mutation

Unknown status·MMediclinic Middle East·Phase 2·NCT03879174·25 enrolled

Evaluation of Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated With Metronomic Cyclophosphamide

Completed·CCentre Leon Berard·Phase 2·NCT03139851·36 enrolled

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT04895358·340 enrolled

Effect of Pembrolizumab (Keytruda®) on Biomarkers in Early Breast Cancer.

Completed·UUniversitaire Ziekenhuizen KU Leuven·Phase 1·NCT03197389·54 enrolled

Non-Small Cell Lung Cancer11 trials

Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

Recruiting·WWake Forest University Health Sciences·Phase 2·NCT04253964·105 enrolled

Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm

Recruiting·—·Phase 2·NCT04317534·244 enrolled

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT06692738·880 enrolled

Show 8 more trials

A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT02775435·559 enrolled

Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)

Completed·YYale University·Phase 2·NCT02681549·41 enrolled

Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT05609968·614 enrolled

A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Recruiting·IImperial College London·Phase 3·NCT05085028·1,750 enrolled

AK112 in Advanced Non-Small Cell Lung Cancer

Active, not recruiting·AAkeso·Phase 3·NCT05499390·398 enrolled

Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT04956692·531 enrolled

Analysis of Gut Microbiota in Patients With Brain Metastasis of Non-small Cell Lung Cancer Treated by Pembrolizumab Combined With Chemotherapy

Unknown status·XXiaorong Dong·Phase 1/2·NCT04333004·40 enrolled

Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT02142738·305 enrolled

Melanoma7 trials

Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma

Terminated·KKaryopharm Therapeutics Inc·Phase 2·NCT04768881·15 enrolled

A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma

Terminated· Roche logo

Roche·Phase 3·NCT03273153·446 enrolled

Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma

Withdrawn·JJames Isaacs, MD·Phase 1·NCT06190249

Show 4 more trials

Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma

Completed·UUniversity of Colorado, Denver·Phase 1/2·NCT03200847·26 enrolled

Relative Bioavailability Study of Subcutaneous Injection Versus Intravenous Infusion of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-555/KEYNOTE-555)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT03665597·138 enrolled

Imatinib Mesylate in Combination With Pembrolizumab in Patients With Melanoma

Unknown status·KKeio University·Phase 1/2·NCT04546074·22 enrolled

A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma.

Completed· Roche logo

Roche·Phase 2·NCT03815058·131 enrolled

Lung Cancer6 trials

Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer

Recruiting·CCanadian Cancer Trials Group·Phase 2/3·NCT04093167·230 enrolled

Pharmacokinetically-guided on the Individualization of Pembrolizumab Administration in the Treatment of Lung Cancer

Completed·SSun Yat-sen University·Phase 1·NCT05226728·33 enrolled

A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer

Completed·BBioNTech US Inc.·Phase 1·NCT03380871·38 enrolled

Show 3 more trials

Pembrolizumab Plus Amurubicin in Patients With Refractory Small-cell Lung Cancer

Unknown status·WWakayama Medical University·Phase 2·NCT03253068·25 enrolled

De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction

Recruiting·IIntergroupe Francophone de Cancerologie Thoracique·Phase 2/3·NCT05255302·1,360 enrolled

Maintenance Pembrolizumab at Usual or Low doSE in Non-squamous Lung Cancer: a Non-inferiority Study

Recruiting·GGustave Roussy, Cancer Campus, Grand Paris·Phase 3·NCT05692999·1,166 enrolled

89 more indications

Metastatic Melanoma6 trials

Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia

Recruiting·IInstitute of Oncology Ljubljana·N/A·NCT07422779·100 enrolled

A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)

Completed· Incyte logo

Incyte·Phase 3·NCT02752074·706 enrolled

Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma

Terminated·RRalph Hauke·Phase 2·NCT03476174·1 enrolled

Show 3 more trials

A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma

Active, not recruiting·EEvaxion Biotech A/S·Phase 2·NCT05309421·17 enrolled

To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.

Unknown status·IIntergruppo Melanoma Italiano·Phase 2·NCT03514901·120 enrolled

IFN-Gamma Expression as a Predictor of Response to Immune Checkpoint Inhibitors in First-Line Metastatic Melanoma

Completed·IInstitute of Oncology Ljubljana·N/A·NCT07436390·132 enrolled

Advanced Solid Tumors5 trials

Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)

Completed· Merck & Co. logo

Merck & Co.·Phase 1/2·NCT03179436·415 enrolled

Study of MK-1248 With and Without Pembrolizumab (MK-3475) for Participants With Advanced Solid Tumors (MK-1248-001)

Terminated· Merck & Co. logo

Merck & Co.·Phase 1·NCT02553499·37 enrolled

A Phase 1 Study of APX-343A as Monotherapy or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Recruiting·AAptabio Therapeutics, Inc.·Phase 1·NCT07123415·110 enrolled

Show 2 more trials

A Phase 1 Study of ZL-1218 in Subjects With Advanced Solid Tumors

Terminated·ZZai Lab (Hong Kong), Ltd.·Phase 1·NCT05859464·34 enrolled

Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors

Recruiting·PPyxis Oncology, Inc·Phase 1/2·NCT06795412·220 enrolled

Lymphoma5 trials

A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05355051·24 enrolled

A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT06504394·66 enrolled

Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymphoma

Recruiting·UUniversity of Cologne·Phase 2·NCT04838652·29 enrolled

Show 2 more trials

Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Completed·KKami Maddocks·Phase 1·NCT02950220·2 enrolled

Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma

Recruiting·NNational Cancer Centre, Singapore·Phase 2·NCT06160843·24 enrolled

Ovarian Cancer4 trials

Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer

Active, not recruiting·RRobert Edwards·Phase 1/2·NCT03734692·24 enrolled

Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT02440425·42 enrolled

PEMBRO With Chemo in Neo Adj Treatment of Ovarian Cancer .

Completed·AARCAGY/ GINECO GROUP·Phase 2·NCT03275506·91 enrolled

Show 1 more trial

Pembrolizumab and Anlotinib in the Treatment of High-Grade Serous Ovarian Cancer

Completed·TThe Affiliated Hospital of Qingdao University··NCT05188781·34 enrolled

Neoadjuvant Therapy4 trials

4 Courses vs 2 Courses of Pembrolizumab Combined With Carboplatin and Albumin-binding Paclitaxel of Neoadjuvant Therapy in HNSCC

Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT05980702·192 enrolled

Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell

Recruiting·TTang-Du Hospital·Phase 2·NCT06006650·114 enrolled

Neoadjuvant Therapy of Pembrolizumab Plus Lenvatinib in Advanced RCC

Completed·TTianjin Medical University Second Hospital·Phase 2·NCT05485896·23 enrolled

Show 1 more trial

Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT02690558·39 enrolled

Small Cell Lung Cancer4 trials

Pembrolizumab and Paclitaxel in Refractory Small Cell Lung Cancer

Completed·SSeoul National University Hospital·Phase 2·NCT02551432·26 enrolled

Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC)

Recruiting·IIstituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS·Phase 2·NCT05623319·60 enrolled

Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT05224141·460 enrolled

Show 1 more trial

Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT04725188·255 enrolled

Bladder Cancer3 trials

Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

Terminated·UUniversity of Oxford·Phase 1/2·NCT03167151·6 enrolled

Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer

Completed·MMatthew Galsky·Phase 2·NCT02500121·108 enrolled

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

Enrolling by invitation·RRondo Therapeutics·Phase 1·NCT07218003·149 enrolled

Squamous Cell Carcinoma3 trials

1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck

Active, not recruiting·UUniversity of Maryland, Baltimore·Phase 2·NCT04150900·7 enrolled

Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

Completed·UUniversity of California, San Diego·Phase 2·NCT03082534·78 enrolled

A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Completed·BBioAtla, Inc.·Phase 2·NCT05271604·42 enrolled

Colorectal Cancer3 trials

NEOadjuvant PembRolizumab In Stratified Medicine - ColoRectal Cancer

Recruiting·UUniversity College, London·Phase 2·NCT05197322·78 enrolled

Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer

Terminated·TTargovax ASA·Phase 1·NCT02933944·6 enrolled

PD-1 Inhibitor Combined With Bevacizumab and FOLFIRI Regimen in the Second-line Treatment of Advanced Colorectal Cancer

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT05035381·10 enrolled

Triple-Negative Breast Cancer3 trials

Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer

Completed·—·Phase 2·NCT03121352·30 enrolled

Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer

Unknown status·NNuGenerex Immuno-Oncology·Phase 2·NCT04024800·29 enrolled

A Phase II Study Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Therapy for Triple-negative Breast Cancer

Unknown status·—·Phase 2·NCT05681728·26 enrolled

Head and Neck Cancer3 trials

Combination Therapy With NC-6004 and Pembrolizumab in Head and Neck Cancer Subjects Who Have Failed Platinum Regimen

Unknown status·NNanoCarrier Co., Ltd.·Phase 2·NCT03771820·136 enrolled

Hemopurifier Plus Pembrolizumab in Head and Neck Cancer

Terminated·AAethlon Medical Inc.·N/A·NCT04453046·2 enrolled

Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer

Active, not recruiting·—·Phase 2·NCT03383094·126 enrolled

Urothelial Carcinoma3 trials

Pembrolizumab and Nab Paclitaxel in Patients With Metastatic Urothelial Carcinoma

Completed·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT03464734·70 enrolled

Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma

Active, not recruiting·FFox Chase Cancer Center·Phase 2·NCT05923190·60 enrolled

A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial Carcinoma

Recruiting·VVasgene Therapeutics, Inc·Phase 2·NCT04486781·38 enrolled

Gastric Cancer3 trials

Exploratory Single-arm, Single-center Adjuvant Treatment of Stage IIIB-IIIC Gastric Cancer With Combination of Palizumab and SOX Regimen

Recruiting·SShanghai Minimally Invasive Surgery Center·Phase 2·NCT06036745·20 enrolled

Pembrolizumab and Trifluridine/Tipiracil With Previously Treated Advanced Gastric Cancer

Active, not recruiting·YYonsei University·Phase 1/2·NCT05508737·75 enrolled

Pembrolizumab Plus Ramucirumab in Metastatic Gastric Cancer

Unknown status·SSamsung Medical Center·Phase 2·NCT04632459·35 enrolled

Diffuse Large B-Cell Lymphoma2 trials

Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT02446457·53 enrolled

Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients

Completed· Novartis logo

Novartis·Phase 1·NCT03630159·12 enrolled

Metastatic NSCLC2 trials

ATL001 in Patients With Advanced Unresectable or Metastatic NSCLC

Terminated·AAchilles Therapeutics UK Limited·Phase 1/2·NCT04032847·27 enrolled

Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004)

Active, not recruiting·PPeking Union Medical College Hospital·Phase 2·NCT05599789·47 enrolled

Advanced Urothelial Cancer2 trials

A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT02256436·542 enrolled

Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer

Not yet recruiting·GGenerate Biomedicines·Phase 1·NCT07484022·37 enrolled

Safety and Efficacy2 trials

Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer

Terminated·AAduro Biotech, Inc.·Phase 1/2·NCT02575807·35 enrolled

A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers

Completed·CCytovation AS·Phase 1/2·NCT05383170·6 enrolled

Renal Cell Carcinoma2 trials

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT04736706·1,653 enrolled

Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT02853344·275 enrolled

Biliary Tract Cancer2 trials

GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer

Terminated·GGenome & Company·Phase 2·NCT05998447·10 enrolled

Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer

Recruiting·PPeking Union Medical College Hospital·Phase 2·NCT06230471·60 enrolled

Immunotherapy2 trials

KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC

Terminated·CCalithera Biosciences, Inc·Phase 2·NCT04265534·40 enrolled

Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations

Completed·UUNICANCER·Phase 2·NCT04357873·112 enrolled

Glioblastoma2 trials

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

Recruiting·NNovoCure GmbH·Phase 3·NCT06556563·741 enrolled

Neoadjuvant Chemoimmunotherapy in Recurrent Glioblastoma

Unknown status·UUniversity of Louisville·Phase 1·NCT05700955·30 enrolled

Advanced NSCLC2 trials

Pembrolizumab After SBRT Versus Pembrolizumab Alone in Advanced NSCLC

Completed·TThe Netherlands Cancer Institute·Phase 2·NCT02492568·92 enrolled

A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.

Not yet recruiting·PPeking Union Medical College Hospital·Phase 2·NCT06142617·37 enrolled

Metastatic Cancer2 trials

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated or Viral Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab

Withdrawn·NNational Cancer Institute (NCI)·Phase 2·NCT04536922

Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers

Recruiting·UUniversity of Chicago·Phase 1·NCT04295863·264 enrolled

Head and Neck Squamous Cell Carcinoma2 trials

Reduction in the Number of Chemotherapy Cycles in Combination With Pembrolizumab in First-line Treatment of PD-L1-positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinomas

Recruiting·IInstitut Claudius Regaud·Phase 2·NCT06557889·86 enrolled

Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Active, not recruiting·PPDS Biotechnology Corp.·Phase 3·NCT06790966·351 enrolled

Cervical Cancer2 trials

PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer

Recruiting·PPrecigen, Inc·Phase 2·NCT06157151·46 enrolled

Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer

Terminated·UUniversity of South Alabama·Phase 2·NCT04230954·5 enrolled

Adjuvant Treatment2 trials

Anti PD-1 Neo-adjuvant Treatment for NSCLC

Completed·JJair Bar, M.D., Ph.D.·Phase 1·NCT02938624·28 enrolled

Pembrolizumab Plus Lenvatinib in REcurrent ccRCC Patients Failing permbroLizUmab aDjuvant trEatment

Not yet recruiting·GGruppo Oncologico Italiano di Ricerca Clinica·Phase 2·NCT07460206·108 enrolled

Soft Tissue Sarcoma2 trials

Pembrolizumab in Combination With Eftilagimod Alpha and Radiotherapy in Neoadjuvant Treatment of Patients With Soft Tissue Sarcoma - EFTISARC-NEO Trial

Active, not recruiting·MMaria Sklodowska-Curie National Research Institute of Oncology·Phase 2·NCT06128863·40 enrolled

Pazopanib With or Without Pembrolizumab for Metastatic Soft Tissue Sarcoma

Recruiting·YYonsei University·Phase 2·NCT05679921·116 enrolled

Metastatic Colorectal Cancer2 trials

A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer

Active, not recruiting· Pfizer logo

Pfizer·Phase 2·NCT05217446·107 enrolled

Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer

Recruiting·CCelyad Oncology SA·Phase 1·NCT04991948·34 enrolled

Advanced Cancers2 trials

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

Recruiting·TTizona Therapeutics, Inc·Phase 1·NCT04485013·240 enrolled

Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers

Completed·AAaron Miller·Phase 1·NCT03568058·25 enrolled

Advanced Cancer1 trial

Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)

Terminated·WWestern Regional Medical Center·Phase 1/2·NCT02331251·81 enrolled

Locally-advanced Rectal Cancer1 trial

Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT02921256·363 enrolled

Metastatic Tumors1 trial

Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors

Completed· Roche logo

Roche·Phase 1·NCT02794571·518 enrolled

Platinum-resistant1 trial

Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer

Unknown status·UUniversity College, London·Phase 2·NCT03430700·28 enrolled

Muscle-invasive Urothelial Cancer of the Bladder1 trial

Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder

Active, not recruiting·NNYU Langone Health·Phase 2·NCT02621151·60 enrolled

Genitourinary Cancer1 trial

A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers

Terminated·WWeill Medical College of Cornell University·Phase 2·NCT03115801·6 enrolled

Prostate Cancer1 trial

Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT03406858·15 enrolled

Classic Hodgkin Lymphoma1 trial

PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05922904·25 enrolled

Patients With Advanced Solid Tumors1 trial

Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors

Active, not recruiting·UUniversity Health Network, Toronto·Phase 2·NCT02644369·100 enrolled

Thoracic Tumors1 trial

AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).

Recruiting· Amgen logo

Amgen·Phase 1·NCT06333951·500 enrolled

Malignant Glioma1 trial

Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·N/A·NCT02658279·27 enrolled

Newly Diagnosed1 trial

Study of Azacitidine in Combination With Pembrolizumab in R/R AML Patients and in Newly Diagnosed Older Patients

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT02845297·67 enrolled

Fallopian Tube Cancer1 trial

Pembrolizumab With Chemotherapy in Front Line Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer

Unknown status·NNational Cancer Institute, Naples·Phase 2·NCT03410784·72 enrolled

Brain Metastases1 trial

Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases

Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT07011849

Pleural Mesothelioma1 trial

Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1/2·NCT03126630·49 enrolled

Squamous Cell Cancer of the Head and Neck1 trial

Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT05172258·52 enrolled

Hematological Malignancies1 trial

Dual PD-1 and JAK2 Inhibition in Hematological Malignancies

Withdrawn·NNYU Langone Health·Phase 2·NCT04016116

Glioma1 trial

Pilot Study of Pembrolizumab Combined With Pemetrexed or Abemaciclib for High Grade Glioma

Withdrawn·JJose Carrillo·Phase 1·NCT04220892

Clear Cell Renal Carcinoma1 trial

Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma

Unknown status·AAustralian and New Zealand Urogenital and Prostate Cancer Trials Group·Phase 2·NCT03280667·59 enrolled

Chemotherapy1 trial

Dynamic PET/CT Evaluated the Response of Neoadjuvant Anti-PD1 Combination With Chemotherapy for Ⅱa-Ⅲb NSCLC

Unknown status·FFifth Affiliated Hospital, Sun Yat-Sen University·Phase 2·NCT04586465·23 enrolled

Gastroesophageal Junction Adenocarcinoma1 trial

A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT02335411·318 enrolled

Adrenocortical Carcinoma1 trial

Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinoma.

Recruiting·MMaria Sklodowska-Curie National Research Institute of Oncology·Phase 2·NCT05563467·24 enrolled

Immune Checkpoint Inhibition1 trial

Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition

Completed·WWake Forest University Health Sciences·Phase 2·NCT04454489·21 enrolled

Metastasis1 trial

Pembrolizumab in Combination with Flutamide Treatment for Recurrence / Metastasis HNSCC

Not yet recruiting·ZZhejiang Provincial People's Hospital·Phase 2·NCT06694350·54 enrolled

Progressive Multifocal Leukoencephalopathy1 trial

Pembrolizumab in Progressive Multifocal Leukoencephalopathy (PML) in Immunocompromised Patients Without HIV Infection

Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2/3·NCT06276504·33 enrolled

Solid Tumor Cancer1 trial

A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT05859074·56 enrolled

Immune Checkpoint Inhibitor1 trial

Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint Inhibitor

Withdrawn·YYale University·Phase 2·NCT04179110

Renal Medullary Carcinoma1 trial

Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma

Recruiting·GGiuseppe Procopio·Phase 2·NCT06302569·23 enrolled

Ablation1 trial

Anti-PD-1therapy Combined With Thermal Ablation for Advanced HCC

Completed·SSun Yat-sen University·Phase 2·NCT03939975·50 enrolled

Locally Advanced1 trial

Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer

Not yet recruiting·PProf. Dr. Remi A. Nout·Phase 2·NCT07368985·87 enrolled

Clear Cell Adenocarcinoma1 trial

Trial of Lenvatinib Plus PembrolizumAb in Recurrent Gynecological Clear Cell Adenocarcinomas (LARA)

Unknown status·NNational University Hospital, Singapore·Phase 2·NCT04699071·10 enrolled

Hematologic Malignancies1 trial

A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01B/LIGHTBEAM-U01)

Withdrawn· Merck & Co. logo

Merck & Co.·Phase 1/2·NCT06395090

Hepatocellular Carcinoma1 trial

Pembrolizumab and Lenvatinib for Resectable Hepatocellular Carcinoma

Active, not recruiting·SShanghai Zhongshan Hospital·Phase 2·NCT05389527·43 enrolled

Immunochemotherapy1 trial

Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLC

Recruiting·HHunan Province Tumor Hospital·Phase 3·NCT05549037·210 enrolled

Adrenal Cortical Carcinoma1 trial

Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma

Active, not recruiting·NNational Cancer Center, Korea·Phase 2·NCT05036434·30 enrolled

Thyroid Cancer1 trial

Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer

Recruiting·SSaint Petersburg State University, Russia·Phase 2·NCT06374602·20 enrolled

Kidney Cancer1 trial

Efficacy of PErioperative PEmbrolizumab Treatment in Patients With Resectable Metastases From Kidney Cancer

Unknown status·CConsorzio Oncotech·Phase 2·NCT05578664·81 enrolled

Kaposi Sarcoma1 trial

Pembrolizumab Plus Lenvatinib in Previously Treated Classic Kaposi Sarcoma

Withdrawn·FFondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico·Phase 2·NCT05846724

Advanced Malignancies1 trial

BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

Recruiting·BBioInvent International AB·Phase 1/2·NCT04752826·176 enrolled

Mucosal Melanoma1 trial

Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Acral and Mucosal Melanoma Patients Progressed From Prior Immune Check Point Inhibitor

Terminated·YYonsei University·Phase 2·NCT05436990·14 enrolled

First Line Therapy1 trial

Study of Pembrolizumab Combined with Chemotherapy in the First Line Therapy for R/M HNSCC in China

Recruiting·YYuankai Shi·Phase 2·NCT04857164·150 enrolled

Renal Cell Cancer1 trial

A Study Evaluating the Effect of Pembrolizumab (MK-3475) in Participants With Renal Cell Cancer (MK-3475-031)

Terminated· Merck & Co. logo

Merck & Co.·Phase 1·NCT02212730·10 enrolled

Gastroesophageal Junction Cancer1 trial

Safety and Efficacy of Pembrolizumab in Combination With FLOT About Gastroesophageal Junction Cancer:

Not yet recruiting·Xxiaohua li·Phase 3·NCT06411171·36 enrolled

Trial1 trial

Emulation of the KEYNOTE-189 Trial Using Electronic Health Records

Completed·AAetion, Inc.··NCT05908799·1,854 enrolled

PD-1 Inhibitor1 trial

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

Recruiting·PPhanes Therapeutics·Phase 1/2·NCT05431270·40 enrolled

Merkel Cell Carcinoma1 trial

Study of PembrolizumAb combiNeD With Cisplatin or carbOplatin and Etoposide in Treatment naïve Advanced meRkel Cell cArcinoma (MCC)

Not yet recruiting·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT06086288·35 enrolled

Cancer1 trial

CyPep-1 Injections in Cancer Inducing Lymphocyte Infiltrate Accumulations

Completed·CCytovation AS·Phase 1/2·NCT04260529·60 enrolled

Dendritic Cell1 trial

Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors

Unknown status·UUniversitair Ziekenhuis Brussel·Phase 2·NCT04571632·36 enrolled

Esophageal Adenocarcinoma1 trial

Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma

Recruiting·HHarry H Yoon·Phase 2·NCT04069273·58 enrolled

Relapsed/Refractory Hematological Malignancies1 trial

A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT05005442·192 enrolled

Cutaneous Squamous Cell Carcinoma1 trial

A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT06041802·19 enrolled

Malignant Mesothelioma1 trial

Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma

Unknown status·UUniversity of Leicester·Phase 2·NCT03654833·186 enrolled

Endometrial Cancer1 trial

Pembrolizumab in Combination With Doxorubicin in Advanced, Recurrent or Metastatic Endometrial Cancer

Completed·VVall d'Hebron Institute of Oncology·Phase 2·NCT03276013·48 enrolled

Multiple Myeloma1 trial

Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Completed·MMayo Clinic·Phase 2·NCT03506360·13 enrolled

Rectal Cancer1 trial

Neo-adjuvant Pembrolizumab and Radiotherapy in Localised MSS Rectal Cancer

Recruiting·UUniversity Hospital, Geneva·Phase 2·NCT04109755·25 enrolled

Solid Tumors1 trial

A Study of ASP1012 in Adults With Solid Tumors

Terminated· Astellas logo

Astellas·Phase 1·NCT06171178·15 enrolled

Esophageal Cancer1 trial

Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT04522336·16 enrolled

Phase 11 trial

Phase 1 First-in-human Study of JS014

Unknown status·AAnwita Biosciences·Phase 1·NCT05296772·60 enrolled

Metastatic Prostate Cancer1 trial

Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT

Completed·DDavid Oh·Phase 2·NCT03007732·23 enrolled

Unspecified2 trials

First in Human Study of T3P-Y058-739 (T3P)

Recruiting·TT3 Pharmaceuticals AG·Phase 1/2·NCT05120596·100 enrolled

International Multicentric Study ARON-1

Recruiting·HHospital of Macerata··NCT05287464·1,220 enrolled

Regulatory

FDA Approval Timeline[4]

Sep 4, 2014

Keytruda

BLA 125514

Sep 4, 2014

KEYTRUDA

BLA BLA125514

Sources

References

[1]
ClinicalTrials.gov — 2178 trial records for Pembrolizumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pembrolizumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pembrolizumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (BLA 125514). U.S. Food & Drug Administration.
[5]
PubMed — 5 publications indexed for Pembrolizumab. U.S. National Library of Medicine.
[6]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: PD-1 Inhibitor[2]
Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: Merck & Co.

Key Publications[5]

Pembrolizumab Adjuvant Therapy in Resected Stage IIB/IIC Melanoma

LancetMay 22, 2023DOI: 10.1016/S0140-6736(23)00929-2

Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer

N Engl J MedAug 25, 2022DOI: 10.1056/NEJMoa2206594

Neoadjuvant Pembrolizumab in Early-Stage Triple-Negative Breast Cancer

N Engl J MedMar 3, 2022DOI: 10.1056/NEJMoa2200181

Pembrolizumab in Microsatellite Instability-High Colorectal Cancer

N Engl J MedAug 26, 2021DOI: 10.1056/NEJMoa2107519

Five-Year Survival Outcomes With Pembrolizumab in Advanced NSCLC: KEYNOTE-024

J Clin OncolFeb 22, 2021DOI: 10.1200/JCO.20.03071